U.S. AI in Clinical Trials Market Gains Momentum as Sponsors Embrace Data-Driven Research. Strong CAGR 14.55% | Key Players:- Medidata, IQVIA, Saama Technologies.

The global AI in Clinical Trials market reached US$1.45 billion in 2024, up from US$1.27 billion in 2023, and is projected to reach US$5.06 billion by 2033, growing at a robust CAGR of 14.55% from 2025 to 2033. The market's rapid expansion is primarily driven by the rising adoption of artificial intelligence technologies to enhance clinical trial efficiency, reduce costs, and accelerate drug development timelines. Increasing data availability from electronic health records (EHRs), genomics, and real-world evidence is enabling AI algorithms to optimize patient recruitment, predict trial outcomes, and improve protocol design.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/ai-in-clinical-trials-market?pratik

Key Industry Developments
✅ December 2025: IQVIA expanded its AI-powered clinical trial platform with predictive patient matching algorithms, reducing recruitment timelines by up to 40% and enhancing diversity in trial enrollment for oncology studies across U.S. sites.

✅ November 2025: FDA issued new guidelines endorsing AI-driven synthetic data generation for clinical trials, accelerating virtual patient modeling and cutting costs for rare disease studies in the U.S. market.

✅ October 2025: Medidata launched AI-enhanced trial simulation software in the U.S., improving protocol design efficiency by 35% and supporting adaptive trial methodologies for faster regulatory approvals.

✅ November 2025: Takeda Pharmaceutical partnered with AI firms in Japan to deploy machine learning for real-world evidence integration in clinical trials, boosting patient retention by 25% in immunology studies.

✅ October 2025: Japanese PMDA approved AI-based patient stratification tools for oncology trials, enabling precise cohort selection and reducing dropout rates amid rising demand for personalized medicine.

✅ September 2025: Eisai introduced an AI platform for trial monitoring in Japan, featuring automated adverse event detection that shortened data review cycles by 30% for neurodegenerative drug candidates.

Recent M&A Activity:-
◾ Clario - strengthened its leadership in AI-powered clinical trial solutions through the acquisition of WCGS eCOA in October 2025, integrating advanced electronic clinical outcome assessment technologies to streamline data collection and enhance regulatory compliance in global trials.

◾ VisiQuate - expanded its AI capabilities in clinical and revenue cycle management by acquiring Rotera in 2025, incorporating large language model-based automation to optimize pre-authorizations, claims processing, and trial-related analytics for pharmaceutical sponsors.

◾ Cortechs.ai - bolstered its neuroimaging AI portfolio relevant to clinical trials with the acquisition of ZepMed's intellectual property, including FDA-cleared NeuroAlign CT software, in October 2025, enabling faster automation of head CT segmentation and neurological change detection.

Key Players:-
Top companies in the AI in Clinical Trials market include Medidata, IQVIA, Saama Technologies, Phesi, Euretos, Median Technologies, Innoplexus, Deep6.ai, AiCure, Antidote Technologies, Mendel AI, among others.

key Player Highlights:-
Medidata:- Medidata (Dassault Systèmes) dominates with its AI-powered cloud platform for trial design, patient matching, and data analytics, accelerating timelines by up to 30%. Estimated market share: 25%. Focuses on end-to-end eClinical solutions for global pharma.

IQVIA:- IQVIA excels in AI-driven site selection, enrollment prediction, and real-world evidence integration, boosting recruitment by 20%+ in oncology trials. Estimated market share: 20%. Leverages vast datasets for decentralized trial efficiency.

Saama Technologies:- Saama's AI platform streamlines spend monitoring, timelines, and quality via predictive analytics on at-risk sites and patient dropouts. Estimated market share: 10%. Enables role-based dashboards for stakeholders in global trials.

Phesi:- Phesi uses AI for patient recruitment, protocol optimization, and real-world data synthesis, reducing trial delays significantly. Estimated market share: 8%. Strong in evidence-based site feasibility across therapeutic areas.

Euretos:- Euretos specializes in AI for target identification and trial simulation using knowledge graphs from biomedical data. Estimated market share: 5%. Enhances early-phase trial success through predictive modeling.

📌 Buy Now & Unlock 360° Market Intelligence:https://www.datamintelligence.com/buy-now-page?report=ai-in-clinical-trials-market?pratik

Key Growth Drivers
◾ Rising R&D Costs: AI cuts traditional trial expenses by up to 30% through automated data analysis and patient matching, addressing pharma's ballooning budgets.

◾ Patient Recruitment Speed: Predictive algorithms identify eligible participants 50% faster using real-world data, slashing enrollment timelines from months to weeks.

◾ Trial Design Optimization: AI enables adaptive protocols and biomarker discovery, improving success rates by 20-25% via precise outcome predictions.

◾ Real-Time Monitoring: Continuous AI analytics reduce errors and enable remote oversight, accelerating data processing in decentralized trials.

◾ Precision Medicine Demand: Chronic disease surge drives AI for personalized therapies, with partnerships boosting adoption in oncology and rare diseases.

Regional Insights:-
North America commands the largest share of the AI in Clinical Trials Market, estimated at around 43% by recent projections, driven by advanced AI innovation hubs, substantial R&D investments from biopharma leaders, robust regulatory frameworks, and high adoption in the US.

Europe follows as the second-largest region, benefiting from established healthcare collaborations, growing AI integration in countries like Germany and the UK, stringent data regulations spurring compliant solutions, and expanding pharma-tech partnerships amid steady market maturation.​

Asia Pacific ranks third in market share, yet exhibits the fastest growth potential with elevated CAGRs in nations such as China, India, and Japan, fueled by surging healthcare digitization, large patient pools for trials, supportive government AI initiatives, and cost-effective research ecosystems

Get Customization in the report as per your requirements:https://www.datamintelligence.com/customize/ai-in-clinical-trials-market?pratik

Market Segmentation-
-By Offering: Software vs Services
Services dominate with 54.73% market share in 2024, driven by demand for specialized AI implementation from CROs and providers handling complex trial stages.
​Software holds 45.27%, growing through adoption in remote monitoring, drug discovery, and risk forecasting tools.​

-By Trial Phase: Phase I vs Phase II vs Phase III
Phase III leads with 55.34% revenue share in 2024, benefiting from large-scale patient recruitment and data analysis needs.
​Phase I and II contribute smaller portions, with Phase I expected at higher growth due to early-stage AI optimization.

-By Indication: Oncology vs CNS Disorders vs CVS Diseases vs Others
Oncology commands 39.02% share in 2024, fueled by high trial volumes, biomarker AI use, and precision medicine focus.
​Infectious diseases also dominate per some reports, while CNS, CVS, and others trail with varying adoption in complex disorder trials.

-By End-User: Pharma/Biotech vs CROs vs Others
Pharmaceutical and biotechnology companies hold 52.67% in 2024 and 59.9% projected for 2025, leveraging R&D investments and data access.
CROs follow at strong growth (26.83% CAGR), offering scalable AI platforms; others like academic centers contribute smaller stable shares

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?pratik

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele

This release was published on openPR.